Skip to Content
scroll

Cyclopharm Ltd (CYC)

CYC $1.06

20 MINUTE DELAYED

14 DAYS FREE ACCESS

Join Market Matters and get full access
to all our Opinion + Action

LEARN MORE

CYC $1.06

20 MINUTE DELAYED

TODAY

20.45 %

1 YEAR RETURN

0.00%

VOLUME

243,325

DIV YIELD

0%

PE RATIO

0.00

52 WEEK RANGE

0.56

2.47

ANALYSIS

i

SHARE PRICE ACTIVITY
Last (Price)

1.06

Change

0.18 (20.45)

Bid / Ask

1.02 - 1.06

Volume

243,325

Turnover

244,906

Open

0.92

Day Range

0.92 - 1.09

VWAP

1.01

Prev Close

0.88

Last Trade

27/01 4:10pm (AEST)

i

KEY INFORMATION
Sector

Healthcare

Shares Issued

57,037,601

NTA/Share

0.00

Last Dividend

0.01

Dividend Ex Date

01 SEP 2023

Dividend Pay Date

11 SEP 2023

i

BROKER CALLS

current

Mean

2.00

Target Price

0.00

BUY

i

CURRENT ()
Revenue

EBITDA

Profit

Earnings Per Share (EPS)

0

Dividend Per Share (DPS)

0

Yield %

0.00

Market Cap

0

Price to Earnings Ratio (P/E)

0

i

TARGET PRICE FORECAST

i

ESTIMATES ()
Revenue

32.25

EBITDA

-14.97

Profit

-11.47

Earnings Per Share (EPS)

-0.10

Dividend Per Share (DPS)

0.00

i

BROKER CONSENSUS RECOMMENDATION

BUY

SELL

Target Price

0.00

Lt Growth Rate

0.00

Recommendation (BUY)

2.00
image description

Business Summary

Cyclopharm Limited is an Australia-based health technology company. The Company specializes in functional lung ventilation imagery. The principal activities of the Company include manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development and distribution of third-party products to the diagnostic imaging sector. Its segments include Technegas and Molecular Imaging. The Technegas segment is a supplier of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and a distributor of third-party products to the diagnostic imaging sector. The Molecular Imaging segment produces radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. It distributes its products under the name Technegas in over 60 countries across the world with approximately 1500 nuclear medicine departments. It also focuses on commercializing its Ultralute technology.

image description

Relevant suggested news and content from the site

image description

Only available to Members

Take a free 14 day Market Matters trial – full access to all our reports, portfolios, positions, buy and sell recommendations. Access the latest views on the latest developments from professional money managers. It's free and no payment details are required
For membership options and pricing. Click here
Back to top